Looking for the latest in oncology clinical literature? You've found the right page. MDLinx Oncology medical editors comb through the top peer-reviewed clinical journals for the articles they think will make a difference to you and your practice. You'll find them organized here by topic including breast, hematologic, thoracic, gastrointestinal and genitourinary cancers. In a matter of minutes, oncologists, oncology nurses, physician assistants and the whole cancer care team can stay current on the literature as it is published.
On this page, you'll also find MDLinx exclusive content, including monthly highlights from our physician editor, D. Scott Cunningham, MD, PhD. We feature clinical pearls as well, from The Smartest Oncologist to oncology topics in The Smartest Pediatrician daily quiz challenges.
Your Unread Messages in Oncology
See All >> Messages include industry-sponsored communications and special communications from MDLinx
D Scott Cunningham MD, PhD
Site Editor, MDLinx
Markers of obesity and inflammation in postmenopausal breast cancer
Jill Baker
MDLinx Career Center
NPs and PAs play crucial role amid PCP shortage
Smartest Doc Challenge
MDLinx
Melanoma Clinical Pearls
MDLinx Reminder
MDLinx
Conference Center Upgraded with New Tools
MDLinx Top Read
MDLinx
Running from that pile of unread journals?
41 Chronic hepatitis E virus infection in a patient with leukemia and elevated transaminases: a case report Full Text Journal of Medical Case Reports, October 3, 2012
42 Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer Full Text BMC Cancer, October 2, 2012
43 Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study Full Text BMC Cancer, October 2, 2012
44 CHD1L protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for patients survival Full Text BMC Cancer, October 2, 2012
45 Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review Full Text BMC Gastroenterology, October 2, 2012 Clinical Article
46 Epstein-Barr virus-positive ileal extraosseous plasmacytoma containing plasmablastic lymphoma components with CD20-positive lymph node involvement Full Text International Journal of General Medicine, October 2, 2012
47 Plexiform schwannoma of the duodenum accompanying pyloric stenosis: Report of a case Full Text The Turkish Journal of Gastroenterology, October 2, 2012
48 Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer Full Text Journal of Clinical Oncology, October 1, 2012 Original Publication Date: August 31, 2011 Clinical Article
49 Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer Full Text New England Journal of Medicine, October 1, 2012 Original Publication Date: March 30, 2012 Clinical Article
50 A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study Full Text Annals of Oncology, October 1, 2012 Original Publication Date: October 3, 2011 Clinical Article
51 Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group Full Text Journal of the National Cancer Institute, October 1, 2012 Original Publication Date: October 3, 2011
52 Long-Term Risk of Colorectal Cancer After Negative Colonoscopy Full Text Journal of Clinical Oncology, October 1, 2012 Original Publication Date: September 1, 2011
53 Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths Full Text Annals of Oncology, October 1, 2012 Original Publication Date: October 3, 2011
54 redictors and Outcomes of Limited Resection for Early-Stage Non–Small Cell Lung Cancer Full Text Journal of the National Cancer Institute, October 1, 2012 Original Publication Date: October 3, 2011
55 Obesity and prostate cancer: gene expression signature of human periprostatic adipose tissue Full Text BMC Medicine, October 1, 2012
56 Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy Full Text Annals of Oncology, October 1, 2012 Original Publication Date: October 3, 2011
57 Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin Full Text Investigational New Drugs, October 1, 2012 Clinical Article
58 A Prospective Comparison of 18F-FDG PET/CT and CT as Diagnostic Tools to Identify the Primary Tumor Site in Patients with Extracervical Carcinoma of Unknown Primary Site Full Text The Oncologist, October 1, 2012
59 Design of a prostate cancer patient navigation intervention for a Veterans Affairs hospital Full Text BMC Health Services Research, October 1, 2012
60 The relationship between obesity and prostate cancer: from genetics to disease treatment and prevention Full Text BMC Medicine, October 1, 2012 Clinical Article
As reported in the Journal of Pathology, the expression of vascular endothelial growth factor receptor (VEGFR)-1 is elevated in invasive hepatocellular cancer (HCC) specimens. In a study based on 135 HCC specimens, elevated VEGFR-1 was also associated with worse recurrence-free and overall survival.
Read the article summaryAs reported in Cancer, researchers from the NCI have reported that patients with AIDS have a 4-fold increased risk of HCC compared to the general population. The study findings were based on 615,150 patients with AIDS between 1980 and 2009. The risk for HCC in patients with AIDS was essentially the same during the monotherapy/dual therapy and highly active anti-retroviral therapy eras.
Read the article summaryAs reported in the International Journal of Cancer Research and Treatment, the pre-operative level of RAB25 is a predictor of disease-free survival (HR=18.2) and overall survival (HR=33.6) in patients with ovarian cancer. The study involved 36 and 16 women with ovarian cancer and benign tumors, respectively. The pre-operative cell-free DNA of genes (B2M, RAB25, CLDN4, and ABCF2) were measured and RAB25 was shown to be an independent prognostic factor.
Read the article summary1 Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial European Journal of Cancer, April 2, 2013
2 R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the FOLL05 Trial conducted by the Fondazione Italiana Linfomi Journal of Clinical Oncology, April 1, 2013
3 Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013 Mayo Clinic Proceedings, April 2, 2013 Clinical Guideline
4 Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Annals of Oncology, April 3, 2013
5 Phase 2 study of dose-intense temozolomide in recurrent glioblastoma Neuro-Oncology, April 9, 2013
6 Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study Journal of the National Cancer Institute, April 4, 2013
7 Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments BMC Cancer, April 3, 2013 Free full text
8 Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27--A Randomized Controlled Phase III Trial Journal of Clinical Oncology, February 11, 2013
9 Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial The Lancet Oncology, March 12, 2013
10 Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study Annals of Oncology, April 1, 2013
11 High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma European Journal of Cancer, April 5, 2013
12 Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial The Lancet Oncology, April 12, 2013
13 Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202) Journal of Clinical Oncology, April 15, 2013
14 Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: Patterns of failure and prognostic factors Cancer, April 11, 2013
15 Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer Cancer, April 10, 2013
16 Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial The Lancet Oncology, February 15, 2013
17 Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab: Results of the randomised GeparQuinto study (GBG 44) European Journal of Cancer, April 5, 2013
18 Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial Annals of Oncology, April 4, 2013
19 Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Annals of Oncology, April 16, 2013
20 R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma British Journal of Haematology, March 1, 2013
Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncology more
Register now to view all the MDLinx contents (FREE)!
Login
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close